Greenwich LifeSciences, Inc. GLSI R2K

Healthcare · Biotechnology · United States

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company also develops FLAMINGO-01, which is in Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.

Market & Price

Market Cap

$362.64M

Current Price

$26.18

High / Low (52W)

$33.56 / $7.85

Beta

1.39

Valuation

Stock P/E

Industry PE

23.65

Forward P/E

PEG Ratio

Book Value

$0.16

Price to Book

165.66

P/S

EV/EBITDA

-18.32

Dividend Yield

Profitability & Returns

ROCE

ROE

ROA

Profit Margin

0.00%

Op Margin

0.00%

EPS (Latest Qtr)

$-0.30

EPS (TTM)

$-1.46

Balance Sheet & Liquidity

Debt/Equity

Quick Ratio

2.35

Current Ratio

2.35

Debt

Total Assets

$4.09M

Current Assets

$4.09M

Working Capital

$2.53M

Ownership

Promoter Holding

50.71%

Chg in Prom Hold

FII / Inst Holding

13.15%

Chg in FII Hold

Financial Snapshot

Enterprise Value

$358.84M

Total Revenue (TTM)

EBITDA

$-19.58M

Free Cash Flow

$-1.36M

Operating Cash Flow

$-8.59M

Shares Outstanding

13.85M

Gross Margin

0.00%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

Profit 5Y

-81.81%

Revenue (YoY)

Earnings (YoY)

PROS

In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Earnings shrank at -81.8% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	GLSI Greenwich LifeSciences, Inc. R2K	26.18	-	$362.64M	-	-	-	-	-81.81%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Mar 2019	Jun 2019	Sep 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.73M	8.08M	3.28M	4.05M	4.17M
Operating Income	-	-	-336.01K	-244.64K	-210.43K	-256.87K	-600.61K	-753.45K	-866.69K	-1.99M	-773.31K	-2.38M	-2.24M	-1.75M	-2.50M	-2.54M	-2.66M	-2.73M	-8.08M	-3.28M	-4.05M	-4.17M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2.73M	-8.08M	-3.28M	-4.05M	-4.17M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2.67M	-8.04M	-3.26M	-4.03M	-4.15M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-148.73K	-2.60M	-336.01K	-244.64K	-210.43K	-256.87K	-597.01K	-749.75K	-863.12K	-1.97M	-746.07K	-2.32M	-2.12M	-1.63M	-2.39M	-2.47M	-2.61M	-2.67M	-8.04M	-3.26M	-4.03M	-4.15M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-0.06	-0.18	-0.17	-0.13	-0.19	-0.19	-0.20	-0.20	-	-0.25	-0.30	-0.30
R&D Expense	-	-	284.50K	149.89K	150.80K	158.03K	281.98K	556.53K	657.10K	1.66M	633.25K	1.72M	1.83M	1.38M	2.16M	2.19M	2.31M	2.29M	-	2.60M	3.51M	3.52M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Revenue	-	-	0	0	0	0
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expenses	-	-	4.60M	8.04M	9.33M	16.01M
Operating Income	-3.43M	-1.86M	-4.60M	-8.04M	-9.33M	-16.01M
EBITDA	-	-	-4.59M	-8.04M	-9.32M	-16.01M
Interest Expense	-	-	-	-	-	-
Pretax Income	-	-	-4.57M	-7.83M	-8.89M	-15.79M
Tax Provision	-	-	-	-	-	-
Net Income	-3.43M	-1.86M	-4.57M	-7.83M	-8.89M	-15.79M
Diluted EPS	-	-	-0.35	-0.61	-0.69	-1.21
R&D Expense	2.61M	1.06M	3.56M	6.48M	7.70M	12.95M

Compounded Sales Growth

5 Years:	-
1 Year:	-

Compounded Profit Growth

5 Years:	-81.81%
1 Year:	-

Stock Price Performance

1 Year:	+165.74%
6 Months:	+211.61%
3 Months:	-5.57%
1 Month:	+21.18%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Assets	-	26.67K	28.68M	27.22M	13.48M	6.99M	4.09M
Current Assets	-	-	-	27.20M	13.47M	6.99M	4.09M
Cash & Equivalents	-	6.83K	28.66M	27.20M	13.47M	6.99M	4.09M
Inventory	-	-	-	-	-	-	-
Receivables	-	-	-	-	-	-	-
Total Liabilities	-	1.38M	1.05M	385.17K	262.90K	294.41K	1.56M
Current Liabilities	-	1.38M	1.05M	385.17K	262.90K	294.41K	1.56M
Long Term Debt	-	-	-	-	-	-	-
Total Debt	-	-	-	-	-	-	-
Total Equity	-10.12M	-1.35M	27.63M	26.83M	13.21M	6.70M	2.53M
Shares Outstanding	-	-	-	13.15M	12.85M	12.85M	13.15M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Operating Cash Flow	-293.27K	-1.15M	-4.29M	-6.20M	-6.48M	-7.27M
Investing Cash Flow	-	-	-	-	-	-
Financing Cash Flow	215.00K	29.81M	2.84M	-7.54M	0	4.37M
Capital Expenditure	-	-	-	-	-	-
Free Cash Flow	-	-	-4.29M	-6.20M	-6.48M	-7.27M
Net Change in Cash	-	-	-1.46M	-13.74M	-6.48M	-2.90M
Share Buybacks	-	-	-	7.54M	-	-

Ratios (Annual)

Figures in %.

Metric	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Gross Margin %	-	-	-	-	-	-
Operating Margin %	-	-	-	-	-	-
Net Margin %	-	-	-	-	-	-
ROE %	253.6%	-6.7%	-17.0%	-59.2%	-132.7%	-623.1%
ROCE %	253.6%	-6.7%	-17.1%	-60.8%	-139.2%	-631.9%

Shareholding Pattern

Insiders

50.71%

Institutions

13.15%

Public Float

26.68%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	3.13%	433.86K	$11.36M
2	Vanguard Capital Management LLC	2.15%	298.27K	$7.81M
3	Geode Capital Management, LLC	1.12%	155.47K	$4.07M
4	State Street Corporation	0.97%	133.88K	$3.50M
5	Nuveen, LLC	0.64%	88.72K	$2.32M
6	Northern Trust Corporation	0.54%	75.12K	$1.97M
7	Vanguard Portfolio Management LLC	0.43%	58.91K	$1.54M
8	Bank Of New York Mellon Corporation	0.34%	46.52K	$1.22M
9	Vanguard Fiduciary Trust Co	0.32%	44.91K	$1.18M
10	Russell Investments Group, Ltd.	0.29%	39.70K	$1.04M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for GLSI

No recent headlines available.

GLSI · Healthcare